Atlas Trials

A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

Clinical trial NCT04501679 · COMPLETED

Trial details

NCT number
NCT04501679
Sponsor
Galderma R&D
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Prurigo Nodularis
Start date
2020-08-11
Primary completion
2022-03-30
Enrollment
274

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.